SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood shares are facing significant downward pressure following a double miss on revenue and earnings, with investors expressing concern over a sharp decline in crypto-related activity. While the company's long-term pivot toward new initiatives like prediction markets and subscription services remains a focal point for bulls, market sentiment is currently dominated by those bracing for further volatility.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is heading into a pivotal earnings release, with the community intensely debating whether the company's consistent growth and potential triple beat can finally overcome a strong bearish sentiment and history of post-earnings volatility. Investors are closely monitoring key metrics like member growth, lending margins, and the performance of the financial services segment as they weigh the stock's long-term potential against heavy short interest and concerns over sector-wide pressures.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is currently seeing significant community buzz following the official completion of its Mistral merger, which has bolstered its defense backlog and direct access to U.S. military contracts. While investors are debating the impacts of dilution and recent share price volatility, sentiment remains split between long-term confidence in the company's drone infrastructure ecosystem and frustration with short-term performance relative to the broader sector.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is actively trending as the community rallies around the launch of LitVM, an EVM-compatible layer-2 solution aimed at bringing smart contracts and DeFi to the ecosystem. While some traders express frustration with price volatility and historical underperformance, others are focused on institutional accumulation through Grayscale and ETF filings, viewing the current range as a significant consolidation period for long-term growth.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is trending as investors debate its long-term viability and price potential amid mixed technical signals and broader market consolidation. The community remains polarized, with many users focused on long-term accumulation and comparing the asset's current performance to other meme coins, while skeptics express frustration over ongoing sideways price action.

Silicon Motion Technology Corp. engages in the development, manufacture, and supply of semiconductor products for the electronics market. Its products include Flash Controllers, Storage Solutions, and others. It offers embedded and expandable storage, radio frequency integrated circuits and embedded graphics. The company was founded in November 1995 and is headquartered in Hong Kong.

Silicon Motion Technology Corp - ADR

Silicon Motion Technology Corp.

Silicon Motion is surging as the market reacts to long-awaited regulatory developments, while the community intensely debates the implications of the pending merger and recent price action. Investors are actively scrutinizing the stock as a high-conviction play on memory cycle recovery and potential M&A outcomes.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility as traders balance optimistic sentiment around institutional accumulation and potential strategic reserve announcements against significant liquidation activity and broader macroeconomic uncertainty. The community remains deeply divided, with many actively debating whether the current price action signals a consolidation phase for a continued uptrend or a looming deeper correction.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is facing intense community debate regarding persistent stock price manipulation, with investors weighing the company's aggressive infrastructure expansion and new product launches against ongoing institutional selling and bearish technical sentiment. While bulls highlight record swap station milestones and upcoming flagship model unveilings as catalysts for a potential reversal, many traders remain frustrated by the stock's sluggish performance relative to its strong delivery growth.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is drawing significant attention as investors weigh disappointing revenue figures against the company's strategic pivot into AI data center infrastructure. While the community remains divided over the stock's long-term valuation and the impact of federal tax credit expirations, many are actively debating whether its recent entry into high-efficiency power solutions for data centers offers a viable path for recovery.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

The community is rallying around Troll's legacy as an original meme, drawing significant attention through active content creation and comparisons to other foundational internet culture tokens. Investors are highlighting its potential for growth as they push the narrative of a return to classic, instantly recognizable memes within the broader memecoin space.

statis crypto Watchlist

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Bloom Energy’s revenue in the quarter ended March 31 surged 130% year-over-year to $751.1 million, above a Wall Street estimate of $540.02.</li><li>The strong start to 2026 comes as the company continues to convert a sizable backlog into deployments across data centers, semiconductor fabs, utilities, and commercial-industrial sites.</li><li>Bloom also lifted its 2026 revenue guidance to a range of $3.4 billion to $3.8 billion — implying roughly 80% year-over-year growth at the midpoint, up from a prior outlook of about 60%.</li></ul> Shares of Bloom Energy (BE) rose 13% after-hours on Tuesday after it reported explosive first-quarter growth and significantly raised its full-year outlook Tuesday, with founder and CEO KR Sridhar declaring the company is rapidly becoming the standard choice for on-site electricity at data centers and other mission-critical facilities.Year-to-date, the stock has already more than doubled on AI-power tailwinds.The results underscore how the artificial-intelligence boom is reshaping power infrastructure: hyperscalers and data-center operators are turning to Bloom’s on-site fuel-cell systems to bypass grid delays and secure the electricity needed for AI training and inference workloads.<h2 class="st-heading-2">Quarterly Numbers</h2>Bloom Energy’s revenue in the quarter ended March 31 surged 130% year-over-year to $751.1 million, driven by a 208% jump in product revenue to $653.3 million, above a Wall Street estimate of $540.02. Adjusted and diluted earnings per share for the quarter came in at $0.44, above an estimated $0.13.Bloom ended the quarter with $2.49 billion in cash and equivalents and generated $73.6 million in operating cash flow, a sharp turnaround from the prior-year outflow. The strong start to 2026 comes as the company continues to convert a sizable backlog into deployments across data centers, semiconductor fabs, utilities, and commercial-industrial sites.<h2 class="st-heading-2">Bloom Energy’s Guidance</h2>Bloom also lifted its 2026 revenue guidance to a range of $3.4 billion to $3.8 billion — implying roughly 80% year-over-year growth at the midpoint, up from a prior outlook of about 60%. Adjusted operating income guidance was set at $600 million to $750 million, with adjusted EPS expected between $1.85 and $2.25.“We at Bloom are ushering in the era of digital power for the digital age,” Sridhar said in prepared remarks. “Bloom is rapidly becoming the standard and ‘go-to choice’ for on-site power.”The company’s momentum has been fueled by major deals tied directly to AI expansion. It recently expanded a partnership with Oracle to deploy up to 2.8 gigawatts of Bloom systems, and it was named the preferred on-site power provider for Brookfield’s AI-factory investments.<h2 class="st-heading-2">How Did Retail Traders React To BE?</h2>On Stocktwits, retail sentiment around BE stock rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levelsA Stocktwits user opined that the stock will open in the green on Wednesday, too.<stembedurl>https://www.stocktwits.com/ScissorHands_/message/651680225</stembedurl>Another user opined that the company’s revenues are still low for its current stock price.<stembedurl>https://www.stocktwits.com/BullrunBull/message/651679918</stembedurl><a href="https://stocktwits.com/symbol/BE">BE stock</a> has rallied 1077% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-says-he-is-openai-shareholder-dismisses-reports-of-company-missing-targets/cZBo7mKRedx">‘Pharma Bro’ Martin Shkreli Says He Is An OpenAI Shareholder, Dismisses Reports Of Company Missing Targets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Bloom Energy (Be) logo is seen displayed on a smartphone screen. 

BE Stock Soars After-Hours As Rising AI Infrastructure Boosts Full-Year Power Demand Outlook

The company’s momentum has been fueled by major deals tied directly to AI expansion. 

Equity

The company’s momentum has been fueled by major deals tied directly to AI expansion. 


<ul class="summary-bullets"><li>In the trial, aimed at evaluating the safety and efficacy of once-weekly Rezzayo, the drug demonstrated a profile comparable with standard antimicrobial regimen in reducing the incidence of invasive fungal infections.</li><li>Rezzayo is already approved in the U.S. for the treatment of candidemia and invasive candidiasis in adults.</li><li>The company estimated that the potential US market opportunity for Rezzayo in preventative care exceeds $2 billion.</li></ul>Shares of CorMedix Therapeutics (CRMD) rose 2% on Monday after the company announced positive results from its late-stage trial evaluating its antifungal drug Rezzayo to prevent invasive fungal diseases (IFDs) in adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).Allogeneic hematopoietic stem cell transplantation is a curative procedure for high-risk blood cancers and marrow diseases, where healthy blood-forming cells from a donor replace a patient's diseased marrow. Patients undergoing the procedure face prolonged periods where their immunity is not strong enough to ward off infections from fungi, including candida, aspergillus, and pneumocystis.Rezzayo is already approved in the U.S. for the treatment of fungal infections, candidemia, and invasive candidiasis in adults. The company estimated that the potential US market opportunity for Rezzayo in preventative care exceeds $2 billion.<h2 class="st-heading-2">Trial Takeaways</h2>In the trial, aimed at evaluating the safety and efficacy of once-weekly Rezzayo, the drug demonstrated a profile comparable with standard antimicrobial regimen in reducing the incidence of invasive fungal infections, the company said. Fungal-free survival at day 90 was 60.7% in the Rezzayo group versus 59.0% in the group that received a standard antimicrobial regimen, it added.Furthermore, the drug was well tolerated with a safety profile showing a favorable benefit/risk profile in the patient population, the company said, while adding that the drug also demonstrated fewer interactions with other drugs and discontinuations due to toxicity.CorMedix now expects to have a meeting with the U.S. Food and Drug Administration in the coming months before submitting an application for the drug for the indication. The company expects to file the application in the second half of 2026 based on the trial results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CRMD jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels. According to internal data, retail chatter around the stock jumped 1400% over the past day.A Stocktwits user expressed optimism for the stock rising into earnings while adding that “today was great news.”<stembedurl>https://www.stocktwits.com/S2730/message/651521499</stembedurl>Another user expressed muted enthusiasm, opining that the results, though good, are not “transformative.”<stembedurl>https://www.stocktwits.com/ReturnOfEsquire/message/651515352</stembedurl> <a href="https://stocktwits.com/symbol/CRMD">CRMD stock</a> has fallen 17% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sndk-stock-surges-nearly-8-to-hit-fresh-record-high-what-s-behind-the-investor-optimism-april-27/cZBND2dReP8">SNDK Stock Surges Nearly 8% To Hit Fresh Record High – What’s Behind The Investor Optimism?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market 

CorMedix now expects to meet with the U.S. Food and Drug Administration in the coming months. 

<ul class="summary-bullets"><li>BTIG added that updated Phase 1 PK/PD data also suggest ORKA-001 could enable once-yearly maintenance dosing, which the firm believes would be a first for any monoclonal antibody.</li><li>The firm raised its price target for Oruka by 94%, to $151 from $78, and maintained a ‘Buy’ rating on the stock.</li><li>Analysts at Guggenheim also hiked their price target for Oruka to $200 from $125, while adding that the company now has the potential to reach a peak of $7 billion in global sales for the psoriasis therapy.</li></ul>Shares of Oruka Therapeutics Inc. (ORKA) were on track for their best single-day gains in more than a month after the company announced interim results from a trial of its moderate-to-severe plaque psoriasis therapy.Oruka Therapeutics announced that 40 of the 63 participants in the EVERLAST-A Phase 2a trial of ORKA-001, a novel, half-life-extended IL-23p19 monoclonal antibody, met the primary endpoint.<a href="https://stocktwits.com/symbol/ORKA">Oruka Therapeutics shares</a> were up more than 20% in Monday’s opening trade.<h2 class="st-heading-2">BTIG Turns Bullish On Oruka</h2>According to TheFly, analysts at BTIG turned bullish on Oruka Therapeutics following the company’s interim trial results. The firm raised its price target for Oruka by 94%, to $151 from $78, and maintained a ‘Buy’ rating on the stock.BTIG added that updated Phase 1 PK/PD data also suggest ORKA-001 could enable once-yearly maintenance dosing, which the firm believes would be a first for any monoclonal antibody.BTIG stated that ORKA-001 has strong potential to become the preferred IL-23 inhibitor if approved, citing best-in-class efficacy and roughly one-fourth the maintenance injection burden of AbbVie’s (ABBV) Skyrizi.Analysts at Guggenheim also hiked their price target for Oruka to $200 from $125, while keeping a ‘Buy’ rating on the stock. The firm believes ORKA-001 has multi-billion-dollar blockbuster potential, adding that Oruka now has the potential to reach a peak of $7 billion in global sales for the psoriasis therapy.<h2 class="st-heading-2">Oruka’s Findings In The Trial</h2>Oruka stated that 64% of the participants in the trial achieved complete skin clearance in the 16th week.The company stated that key secondary endpoints were also strong, with 83% reaching PASI 90 during this period.In the placebo group, one of 21 participants met these endpoints, which it said was consistent with historical psoriasis trials.Oruka stated that cross-trial comparisons suggest ORKA-001 delivers higher skin clearance rates than other IL-23p19 inhibitors and ranks among the best reported in plaque psoriasis across all treatment types.The company stated that it plans to release longer-term EVERLAST-A data in the second half of 2026, including Week 28 results for all patients, along with a 52-week follow-up for a subset. Oruka also added that it will continue to advance the Phase 2b EVERLAST-B trial, with data expected in 2027.PASI refers to the Psoriasis Area and Severity Index. It quantifies the severity and extent of psoriasis symptoms across body regions. PASI 90 refers to a 90% or more improvement. Similarly, PASI 100 denotes a 100% improvement over baseline.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ORKA">Oruka Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels as of this writing.One bullish user believes ORKA stock could reach $200 per share soon.<stembedurl>https://stocktwits.com/Chiefstaff/message/651484000</stembedurl><a href="https://stocktwits.com/symbol/ORKA">ORKA stock</a> is up 172% year-to-date and 716% over the past 12 months. The S&amp;P Biotech ETF (XBI) is up 68% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 42%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/microsoft-loses-exclusive-license-openai-models-taps-anthropic-claude/cZBNAqiRePg">Microsoft Loses Exclusive Access To OpenAI Models In Partnership Reset Ahead Of Q3 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

“We are pleased to have settled our lawsuit with the United States Department of Justice,” the LYV said in a statement as its stock closed higher. 

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%

Oruka Therapeutics stated that 64% of the participants in the Phase 2a EVERLAST-A trial of ORKA-001 met the study’s primary endpoint.

<ul class="summary-bullets"><li>Peloton stated that, starting Monday, Spotify Premium subscribers in most countries worldwide can access a curated selection of fitness content.</li><li>This includes strength, pilates, barre, yoga, stretching, meditation, floor cardio and outdoor classes.</li><li>The company stated that the library features sessions in English, Spanish and German, led by a roster of popular instructors, with new classes and formats added regularly.</li></ul>Peloton Interactive Inc. (PTON) on Monday announced a partnership with Spotify Technology SA (SPOT) to bring its fitness content to the music streaming giant’s 290 million subscribers.The partnership between the two companies is part of Spotify’s plans to ramp up the offerings in its new fitness category. This also gives Peloton’s fitness content the exposure to hundreds of millions of Spotify subscribers around the world, helping the company elevate itself from a fitness equipment maker to a fitness content provider.<a href="https://stocktwits.com/symbol/PTON">Peloton shares</a> were up nearly 7% in Monday’s pre-market trade, on track for the biggest gains in this month so far. PTON was among the top trending tickers on the platform at the time of writing.<h2 class="st-heading-2">From Pilates To Yoga And More</h2>Peloton stated that starting Monday, Spotify Premium subscribers across most countries in the world can access a curated selection of Strength, Pilates, Barre, Yoga, Stretching, Meditation, Floor Cardio and Outdoor classes in Spotify’s new Fitness category.The company stated that the library features sessions in English, Spanish and German, led by a roster of popular instructors, with new classes and formats added regularly.“By bringing Peloton directly into our video and audio ecosystem, we are investing in a future where Spotify isn’t just where you spend your time—it’s where you go to build momentum, improve your wellbeing, and get more out of every day,” said Roman Wasenmüller, VP, Global Head of Podcasts, Spotify.Peloton also stated that this partnership underscores its shift toward a more diversified business model.“With this partnership, we are instantly activating a global footprint that makes the magic of Peloton accessible to Spotify Premium subscribers anywhere,” said Peloton’s Chief Commercial Officer, Dion Camp Sanders.Spotify currently has 751 million users and 290 million subscribers in 184 countries.<h2 class="st-heading-2">Trump Tariff Impact On Peloton</h2>According to TheFly, analysts at UBS stated earlier this month that the Section 232 tariff changes will reduce the levies on aluminum that Peloton uses for its equipment to 25% from 50%.The firm maintained its ‘Buy’ rating on PTON stock with a $11 price target, implying an upside of more than 110% from current levels.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/PTON">Peloton</a> trended in the ‘neutral’ territory, with message volumes at ‘high’ levels at the time of writing.One user thinks that Peloton’s market capitalization should be no less than $20 billion, while it is currently hovering around $2.2 billion.<stembedurl>https://stocktwits.com/DORITOBOI/message/651488886</stembedurl><a href="https://stocktwits.com/symbol/PTON">PTON stock</a> is down 16% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/SPOT">SPOT stock</a> is down 11%. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 31% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 43%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ntla-stock-soars-intellia-positive-gene-therapy-trial/cZBNFouRe2C">NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A Peloton bike is displayed at a Dick's Sporting Goods store on May 08, 2024 in Daly City, California. (Photo by Justin Sullivan/Getty Images)

Peloton’s Spotify Deal Opens Doors To 290M Users: PTON Stock On Track For Best Gains This Month

The partnership between the two companies is part of Spotify’s plans to ramp up the offerings in its new fitness category.

<ul class="summary-bullets"><li>The company stated that 62% of the patients in the trial who received lonvo-z were entirely free of HAE attacks during the six-month evaluation period, compared to 11% of patients who received placebo.</li><li>Lonvo-z is a one-time treatment administered in an outpatient setting.</li><li>Intellia Therapeutics also stated that it has initiated a rolling Biologics License Application submission to the U.S. Food and Drug Administration.</li></ul>Shares of Intellia Therapeutics Inc. (NTLA) soared in Monday’s pre-market trade after the company reported positive Phase 3 trial results in its therapy for a rare genetic condition.<a href="https://stocktwits.com/symbol/NTLA">Intellia Therapeutics shares</a> were up more than 9% before the bell on Monday, on track for the biggest gains in this month so far. NTLA was the top trending ticker on the platform at the time of writing.<h2 class="st-heading-2">Rare Genetic Condition Trial Meets All Endpoints</h2>Intellia Therapeutics stated that its Phase 3 trial of lonvoculin ziclumeran (lonvo-z) met the primary and secondary endpoints, with favorable safety and tolerability.The Cambridge, Massachusetts-based biopharmaceutical company evaluated lonvo-z for the treatment of hereditary angioedema (HAE), a rare genetic condition characterized by recurrent, sometimes life-threatening episodes of swelling (angioedema) in different parts of the body. This includes the face, upper airway, abdomen, and extremities due to bradykinin overproduction.The company designed lonvo-z as a one-time treatment that is administered in an outpatient setting. Lonvo-Z is an in vivo CRISPR gene-editing candidate designed to disable the kallikrein B1 (KLKB1) gene, aiming to permanently reduce kallikrein and bradykinin levels.“For those patients who have spent years battling unpredictable breakthrough swelling attacks, anxiety about their next attack or the many burdens associated with chronic prophylactic treatment, lonvo-z represents a potential paradigm shift in treatment,” said Intellia Therapeutics CEO John Leonard.The company stated that 62% of the patients in the trial who received lonvo-z were entirely free of HAE attacks during the six-month evaluation period, compared to 11% of patients who received a placebo.<h2 class="st-heading-2">Intellia Submits Application For FDA Approval</h2>Intellia Therapeutics also stated that it has initiated a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for approval.It is also preparing for a potential U.S. launch of lonvo-z in the first half of 2027.Intellia Therapeutics stated that it will present additional data at the 2026 European Academy of Allergy and Clinical Immunology Congress in June this year.The company said that one in 50,000 people is estimated to be affected by HAE.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NTLA">Intellia Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One user stated that gene editing is the future.<stembedurl>https://stocktwits.com/2h2guard/message/651485761</stembedurl>Another bullish user recommended investing now before it is too late for the perfect buying opportunity.<stembedurl>https://stocktwits.com/JuniorStocka/message/651485649</stembedurl><a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> is up 52% year-to-date and 67% over the past 12 months. The ARK Innovation ETF (ARKK) is up 53% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 65%.The iShares Russell 2000 ETF (IWM) is up 43% during this period, while the Vanguard Small-Cap Growth Index Fund ETF Shares (VBK) is up 36%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/qcom-stock-highest-level-3-months-wall-street-not-bullish-q2-earnings/cZBNZwBRe2M">QCOM Stock On Track To Open At Highest Levels In 3 Months, But Wall Street Is Cautious Ahead Of Q2 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late

Intellia Therapeutics stated that its Phase 3 trial of lonvoguran ziclumeran met the primary and secondary endpoints, with favorable safety and tolerability.

<ul class="summary-bullets"><li>Mizuho stated in its note that AET Pharma is the sole remaining generic challenger that has yet to settle with Harmony Biosciences.</li><li>The firm believes Harmony’s Wakix franchise should be viewed as protected and fully intact through 2030.</li><li>Mizuho also noted that Harmony's lawsuit is a "significant development" and a "major positive" for the company.</li></ul>Shares of Harmony Biosciences Holdings Inc. (HRMY) soared more than 18% in Tuesday’s midday trade after analysts at Mizuho announced that they have learned of a new patent lawsuit filed by the company.According to TheFly, Mizuho analysts stated that Harmony Biosciences has sued AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.<a href="https://stocktwits.com/symbol/HRMY">Harmony Biosciences shares</a> were up over 14% in Tuesday’s midday trade. Retail sentiment on Stocktwits about the company trended in ‘bullish’ territory, with message volume at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Is The Lawsuit About?</h2>Mizuho stated in its note that AET Pharma is the sole remaining generic challenger that has yet to settle with Harmony Biosciences. The lawsuit covers pitolisant, which was initially developed by Bioprojet and subsequently licensed exclusively by Harmony for the development, manufacture, and commercialization of pitolisant in the U.S.The firm now believes the Harmony Wakix franchise should be considered protected and fully intact through 2030. It also noted that Harmony's lawsuit is a "significant development" and a "major positive" for the company.Mizuho contended that this lawsuit should also remove a major overhang on HRMY stock stemming from concerns that a generic version of pitolisant could be launched before 2030.The firm reiterated its ‘Outperform’ rating on Harmony, with a $50 price target, implying an upside of about 50% from current levels.Koyfin data shows that the average 12-month price target for Harmony is $42, implying an upside of about 27% from current levels. Of the 11 analysts covering the stock, six have either a ‘Strong Buy’ or a ‘Buy’ recommendation, four have a ‘Hold’ rating, and one has a ‘Strong Sell’ recommendation.<h2 class="st-heading-2">What Is Pitolisant Used For?</h2>Pitolisant, originally developed to treat excessive daytime sleepiness and cataplexy in narcolepsy patients, is also being evaluated by Harmony Biosciences for use in individuals with Prader-Willi syndrome.The company also has two pitolisant tablet formulations, namely Pitolisant GR and Pitolisant HD.Harmony is developing Pitolisant GR to enable treatment initiation within the therapeutic dose range. Pitolisant HD is a reformulated version designed to improve how the drug works in the body and to target additional symptoms, such as fatigue, in patients with narcolepsy.Harmony announced in February this year that the U.S. Food and Drug Administration (FDA) approved Wakix (pitolisant) for the treatment of cataplexy in pediatric narcolepsy.“With this approval, clinicians now have the option to prescribe WAKIX to treat excessive daytime sleepiness, cataplexy, or both, in patients 6 years and older with narcolepsy,” said Harmony Biosciences’ Chief Medical and Scientific Officer, Kumar Budur.<a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> is down 10% year-to-date, but up 18% over the past 12 months. The iShares Core S&amp;P Small-Cap ETF (IJR) is up 43% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 51%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/velo-stock-soars-best-gains-4-months-what-is-fueling-rally/cZBI8d9RI6e">VELO Stock Soars 38%, Races Toward Best Single-Day Move In 4 Months — What Is Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say?

Mizuho analysts stated that they have learned that Harmony Biosciences has filed a lawsuit against AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.

Best-Performing Leveraged ETFs of Last Week

Leveraged ETFs like IONL and HIMZ surged last week on easing Iran war fears, strong earnings and quantum buzz, even as Strait of Hormuz risks persist.

Top-Performing ETFs of Last Week 

ETFs rallied last week on easing Iran war fears, strong earnings and crypto buzz, even as Strait of Hormuz risks linger.

<ul class="summary-bullets"><li>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia cells from natural programmed cell death, making them more vulnerable.</li><li>Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.</li><li>Meanwhile, Sellas’s late-stage trial of its lead candidate GPS in Acute Myeloid Leukemia is advancing toward final analysis.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) closed up 6% and edged up 2% after-hours on Friday, garnering heavy retail interest as investors anticipated upcoming data updates on its pipeline at the American Association for Cancer Research.According to Stocktwits platform data, retail chatter increased 36% over the past day, rising from ‘low’ to ‘normal’ levels.Sellas is slated to present preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center. Sellas will make its presentation on April 21.<h2 class="st-heading-2">Pipeline Optimism</h2>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia (AML) cells from natural programmed cell death, making them more vulnerable. Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.“The ability to lower apoptotic threshold in AML cells by suppressing key survival pathways and enhancing potency with repeated exposure further supports the development of SLS009, including in combination regimens,” said Dragan Cicic, Chief Development Officer of SELLAS.Sellas’s lead candidate, GPS, meanwhile, is being evaluated for its potential as a monotherapy and in combination with other therapies to address a broad spectrum of blood malignancies and solid tumor indications.The company’s late-stage trial of GPS in Acute Myeloid Leukemia is advancing toward final analysis. The final analysis is slated for when the company records the 80th patient death in the trial. In December, the company announced that 72 events had been completed and it will announce when the 80th event occurs. With event-driven trials like Sellas’s, the delay highlights longer survival, indicating potential for the therapy.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SLS stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours.A Stocktwits user said that the stock has two near-term catalysts in terms of the upcoming conference and update on the GPS program in AML.<stembedurl>https://www.stocktwits.com/55X_ROI_Q1_2026/message/650652881</stembedurl>Yet another sounded optimistic for the company’s pipeline, highlighting the many designations granted to Sellas’s experimental therapies.<stembedurl>https://www.stocktwits.com/gata2016/message/650649884</stembedurl><a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-on-track-for-best-day-in-nearly-16-months-whats-driving-the-rally/cZJyGq6RIUn">CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy

Sellas is slated to announce preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center.

<ul class="summary-bullets"><li>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma featured in Parade magazine.</li><li>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma.</li><li>New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.</li></ul>Shares of Candel Therapeutics (CADL) jumped 24% on Friday as investors await upcoming clinical data readouts and process positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.The stock is now on track to record its best day since December 2024, if gains hold.<h2 class="st-heading-2">Positive Media Coverage</h2>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma, featured in Parade magazine.Donahue, who was initially given only months to live after her diagnosis, participated in a clinical trial of the company’s investigational viral immunotherapy CAN-3110. Tak described the case as both deeply personal and scientifically meaningful, noting that such outcomes underscore the potential of viral immunotherapies to reshape the tumor microenvironment, activate durable immune responses, and represent a possible turning point in a disease where progress has long been elusive.<h2 class="st-heading-2">Upcoming Catalysts</h2>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma. New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.To add to the momentum, last month, the company announced positive updates for its lead candidate CAN-2409 in patients with advanced non-small cell lung cancer. The company said that extended long-term survival was observed after an additional year of follow-up in an ongoing phase 2a clinical trial, with 50% of 46 patients treated with CAN-2409 surviving beyond 24 months.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CADL stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A few Stocktwits users expressed optimism for an upcoming buyout or partnership for the company.<stembedurl>https://www.stocktwits.com/drizz/message/650628803</stembedurl><stembedurl>https://www.stocktwits.com/gusm17/message/650618195</stembedurl>Another highlighted the positive press published on Parade, terming it “incredibly positive.”<stembedurl>https://www.stocktwits.com/pyroclast/message/650627286</stembedurl><a href="https://stocktwits.com/symbol/CADL">CADL stock</a> has gained 40% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/omer-stock-on-track-for-best-week-in-nearly-four-months-after-receiving-permanent-reimbursement-code-for-treatment/cZJUzYKRIUj">OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?

Candel stock is rallying on the heels of positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.  

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWM News

IWMiShares Russell 2000 ETF